FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia

Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2zSpfj3